LLY

762.79

+0.4%↑

JNJ

174.31

-1.4%↓

ABBV

221.87

+0.84%↑

UNH

334.97

-1.8%↓

AZN

77.08

-0.7%↓

LLY

762.79

+0.4%↑

JNJ

174.31

-1.4%↓

ABBV

221.87

+0.84%↑

UNH

334.97

-1.8%↓

AZN

77.08

-0.7%↓

LLY

762.79

+0.4%↑

JNJ

174.31

-1.4%↓

ABBV

221.87

+0.84%↑

UNH

334.97

-1.8%↓

AZN

77.08

-0.7%↓

LLY

762.79

+0.4%↑

JNJ

174.31

-1.4%↓

ABBV

221.87

+0.84%↑

UNH

334.97

-1.8%↓

AZN

77.08

-0.7%↓

LLY

762.79

+0.4%↑

JNJ

174.31

-1.4%↓

ABBV

221.87

+0.84%↑

UNH

334.97

-1.8%↓

AZN

77.08

-0.7%↓

Search

Recursion Pharmaceuticals Inc

Fermé

SecteurSoins de santé

4.92 4.9

Résumé

Variation du prix de l'action

24h

Actuel

Min

4.69

Max

4.96

Chiffres clés

By Trading Economics

Revenu

31M

-172M

Ventes

4.4M

19M

Marge bénéficiaire

-899.843

Employés

800

EBITDA

44M

-148M

Recommandations

By TipRanks

Recommandations

Neutre

Prévisions sur 12 Mois

+22.93% upside

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

-432M

2.1B

Ouverture précédente

0.02

Clôture précédente

4.92

Score Technique

By Trading Central

Confiance

Very Strong Bearish Evidence

Recursion Pharmaceuticals Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

18 sept. 2025, 23:56 UTC

Actions en Tendance

Stocks to Watch: FedEx, 22nd Century, Scholastic

18 sept. 2025, 22:01 UTC

Principaux Mouvements du Marché

22nd Century Group Shares Gain on Debt Repayment, New Capital

18 sept. 2025, 20:51 UTC

Acquisitions, Fusions, Rachats

UPS Terminates Plan to Buy Estafeta

18 sept. 2025, 20:31 UTC

Résultats

FedEx 1Q Profit, Sales Rise on Improvement in U.S. Shipping -- Update

18 sept. 2025, 20:26 UTC

Résultats

FedEx 1Q Profit, Sales Rise on Improvement in U.S. Shipping

18 sept. 2025, 23:43 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

18 sept. 2025, 23:43 UTC

Market Talk

Nikkei May Rise on U.S. Stock Gains, Weaker Yen -- Market Talk

18 sept. 2025, 23:43 UTC

Market Talk

Global Equities Roundup: Market Talk

18 sept. 2025, 23:40 UTC

Market Talk

Gold Edges Lower Amid Cautious Mood -- Market Talk

18 sept. 2025, 23:31 UTC

Market Talk

FedEx Says U.S. Demand Is Resilient -- Market Talk

18 sept. 2025, 22:03 UTC

Résultats

FedEx Expects Trade Environment to Create $1B Headwind in 2026, CFO Says

18 sept. 2025, 22:01 UTC

Résultats

FedEx CFO: Asia-to-U.S. Declines Drove $150M International Export Headwind

18 sept. 2025, 21:56 UTC

Résultats

Lennar Missed Revenue Estimates. The Stock Is Down. -- Barrons.com

18 sept. 2025, 21:54 UTC

Résultats

FedEx Focused on Demand From Southeast Asia, Europe Amid China Shipping Slowdown, Customer Chief Says

18 sept. 2025, 21:48 UTC

Résultats

FedEx International Export Volumes Declined, Especially on China-to-U.S. Lane, Exec Says

18 sept. 2025, 21:47 UTC

Résultats

FedEx Had 5% Increase in U.S. Domestic Average Daily Package Volume in 1Q, Customer Chief Says

18 sept. 2025, 21:17 UTC

Résultats

FedEx Profit, Sales Rise on Improvement in U.S. Shipping -- 2nd Update

18 sept. 2025, 21:07 UTC

Résultats

FedEx Earnings Were a Relief. The Stock Is Up. -- Barrons.com

18 sept. 2025, 20:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

18 sept. 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

18 sept. 2025, 20:50 UTC

Market Talk
Résultats

Financial Services Roundup: Market Talk

18 sept. 2025, 20:50 UTC

Market Talk

Energy & Utilities Roundup: Market Talk

18 sept. 2025, 20:22 UTC

Acquisitions, Fusions, Rachats

UPS Cites Inability of All Closing Conditions to Be Satisfied

18 sept. 2025, 20:22 UTC

Acquisitions, Fusions, Rachats

United Parcel Service Terminates Plan to Buy Estafeta

18 sept. 2025, 20:20 UTC

Acquisitions, Fusions, Rachats

Here's How Much the U.S. Has Made on Its Intel Stock Purchase -- Barrons.com

18 sept. 2025, 20:18 UTC

Résultats

Nucor Stock Falls After Earnings. Why Its Guidance Was Far Off Rival Steel Dynamics. -- Barrons.com

18 sept. 2025, 20:18 UTC

Résultats

Bullish Crushes Earnings. The Crypto Stock Pops. -- Barrons.com

18 sept. 2025, 20:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

18 sept. 2025, 20:07 UTC

Résultats

FedEx Earnings Were a Relief. The Stock Is Up. -- Barrons.com

18 sept. 2025, 20:03 UTC

Résultats

FedEx 1Q FedEx Freight Segment Revenue $2.26B >FDX

Comparaison

Variation de prix

Recursion Pharmaceuticals Inc prévision

Objectif de Prix

By TipRanks

22.93% hausse

Prévisions sur 12 Mois

Moyen 5.95 USD  22.93%

Haut 8 USD

Bas 3 USD

Basé sur 5 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Neutre

5 ratings

1

Achat

4

Maintien

0

Vente

Score Technique

By Trading Central

4.15 / 4.75Support & Résistance

Court Terme

Very Strong Bearish Evidence

Moyen Terme

Bearish Evidence

Long Terme

Bearish Evidence

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Recursion Pharmaceuticals Inc

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.
help-icon Live chat